2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Carcinoma
2
Sezary Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Rectal Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, Non-Hodgkin
1
Liposarcoma, Myxoid
1
Leukemia, Myeloid
1
Hodgkin Disease
1
HIV Infections
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Cisplatin
13
Etoposide
11
Paclitaxel
8
Cyclophosphamide
7
Carboplatin
7
Ifosfamide
6
etoposide phosphate
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
pembrolizumab
4
fludarabine
4
Sirolimus
4
Bleomycin
4
fludarabine phosphate
3
Sunitinib
3
Oxaliplatin
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bevacizumab
3
Automobiles
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
sodium thiosulfate
2
ribociclib
2
pralsetinib
2
pegfilgrastim
2
lutetium Lu 177 dotatate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled